By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

Novo Nordisk's shares dropped nearly 5% after their experimental obesity pill, monlunabant, showed underwhelming Phase 2a trial results. The pill, acquired through a $1 billion deal with Inversago ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Roche Holding AG said side effects in a highly anticipated study of its experimental obesity pill were milder when it eased ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those ...